Tecfidera
E25438
Tecfidera is an oral disease-modifying medication used to treat relapsing forms of multiple sclerosis by reducing inflammation and relapse frequency.
All labels observed (1)
| Label | Occurrences |
|---|---|
| Tecfidera canonical | 2 |
How this entity was disambiguated
This entity first appeared as the object of triple T195373 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Tecfidera Context triple: [Biogen, hasProduct, Tecfidera]
-
A.
Tysabri
Tysabri is a monoclonal antibody medication primarily used to treat relapsing forms of multiple sclerosis and Crohn’s disease.
-
B.
Aduhelm
Aduhelm is an Alzheimer’s disease drug developed by Biogen that targets amyloid-beta plaques in the brain.
-
C.
Spinraza
Spinraza is a prescription medication used to treat spinal muscular atrophy (SMA) by modifying SMN2 gene expression to increase production of survival motor neuron (SMN) protein.
-
D.
Vumerity
Vumerity is an oral prescription medication used to treat relapsing forms of multiple sclerosis in adults.
-
E.
Biogen
Biogen is a major American biotechnology company known for developing therapies for neurological and neurodegenerative diseases.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Tecfidera Target entity description: Tecfidera is an oral disease-modifying medication used to treat relapsing forms of multiple sclerosis by reducing inflammation and relapse frequency.
-
A.
Tysabri
Tysabri is a monoclonal antibody medication primarily used to treat relapsing forms of multiple sclerosis and Crohn’s disease.
-
B.
Aduhelm
Aduhelm is an Alzheimer’s disease drug developed by Biogen that targets amyloid-beta plaques in the brain.
-
C.
Spinraza
Spinraza is a prescription medication used to treat spinal muscular atrophy (SMA) by modifying SMN2 gene expression to increase production of survival motor neuron (SMN) protein.
-
D.
Vumerity
Vumerity is an oral prescription medication used to treat relapsing forms of multiple sclerosis in adults.
-
E.
Biogen
Biogen is a major American biotechnology company known for developing therapies for neurological and neurodegenerative diseases.
- F. None of above. chosen
Statements (48)
| Predicate | Object |
|---|---|
| instanceOf |
disease-modifying therapy
ⓘ
multiple sclerosis medication ⓘ pharmaceutical drug ⓘ |
| belongsToClass |
fumaric acid esters
ⓘ
immunosuppressive agents ⓘ |
| hasActiveIngredient | dimethyl fumarate ⓘ |
| hasAdministrationFrequency | twice daily ⓘ |
| hasApprovalBy |
European Medicines Agency
ⓘ
Food and Drug Administration ⓘ
surface form:
U.S. Food and Drug Administration
|
| hasATCCode | L04AX07 ⓘ |
| hasChemicalFormula | C6H8O4 ⓘ |
| hasCommonSideEffect |
abdominal pain
ⓘ
diarrhea ⓘ flushing ⓘ nausea ⓘ pruritus ⓘ rash ⓘ vomiting ⓘ |
| hasContraindication | known hypersensitivity to dimethyl fumarate ⓘ |
| hasDosageForm | delayed-release capsule ⓘ |
| hasEffectOn | absolute lymphocyte count ⓘ |
| hasFDAApprovalYear | 2013 ⓘ |
| hasGenericName | dimethyl fumarate ⓘ |
| hasInitialDose | 120 mg twice daily ⓘ |
| hasLegalStatus | prescription-only ⓘ |
| hasMaintenanceDose | 240 mg twice daily ⓘ |
| hasMechanismOfAction |
anti-inflammatory
ⓘ
immunomodulatory ⓘ |
| hasMolecularWeight | 144.13 g/mol ⓘ |
| hasPregnancyCategory | use only if potential benefit justifies potential risk ⓘ |
| hasRouteOfAdministration | oral ⓘ |
| hasSeriousAdverseEffect |
liver injury
ⓘ
lymphopenia ⓘ progressive multifocal leukoencephalopathy ⓘ |
| isManufacturedBy | Biogen ⓘ |
| isProdrugOf | monomethyl fumarate ⓘ |
| isTakenWith | food ⓘ |
| mayCause | flushing mediated by prostaglandins ⓘ |
| reduces |
magnetic resonance imaging lesion activity in multiple sclerosis
ⓘ
relapse frequency in multiple sclerosis ⓘ risk of disability progression in multiple sclerosis ⓘ |
| requiresMonitoring |
liver function tests
ⓘ
lymphocyte count ⓘ |
| targetsPathway | Nrf2 pathway ⓘ |
| treats |
active secondary progressive multiple sclerosis
ⓘ
clinically isolated syndrome ⓘ relapsing forms of multiple sclerosis ⓘ relapsing-remitting multiple sclerosis ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Tecfidera Description of subject: Tecfidera is an oral disease-modifying medication used to treat relapsing forms of multiple sclerosis by reducing inflammation and relapse frequency.
Referenced by (2)
Full triples — surface form annotated when it differs from this entity's canonical label.